Roy Susmit Prosun, Al Zhahrani Nayef, Barat Shoma, Morris David L
General Surgery, John Hunter Hospital, University of Newcastle, Newcastle, Australia; Liver and Peritonectomy Unit, St George Hospital, Kogarah, Australia.
Liver and Peritonectomy Unit, St George Hospital, Kogarah, Australia; College of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
Int J Surg Case Rep. 2022 May;94:107027. doi: 10.1016/j.ijscr.2022.107027. Epub 2022 Apr 4.
Pseudomyxoma Peritonei (PMP) is a mucin producing cancer with appendix as primary site. Cytoreductive Surgery (CRS) combined with hyper-thermic intraperitoneal chemotherapy (HIPEC) is an established form of therapy known to prolong survival in patients with PMP and peritoneal carcinomatosis. Methods/patients In our case series, we present five cases of PMP with synchronous liver and peritoneal metastasis treated with CRS and HIPEC. It is a very rare condition which needs more research to be able to comment on overall survival.
However, in our study, we found lower age, female gender and complete cytoreduction in surgery to be favourable predictors for improved morbidity.
In our experience, CRS/HIPEC seem to be feasible for patients with PMP with synchronous liver and peritoneal metastasis.
腹膜假黏液瘤（PMP）是一种以阑尾为原发部位的产黏液癌。细胞减灭术（CRS）联合热灌注腹腔化疗（HIPEC）是一种已确立的治疗方式，已知可延长PMP和腹膜癌患者的生存期。方法/患者 在我们的病例系列中，我们呈现了5例伴有同步肝转移和腹膜转移的PMP患者，接受了CRS和HIPEC治疗。这是一种非常罕见的情况，需要更多研究才能对总生存期进行评论。
然而，在我们的研究中，我们发现年龄较小、女性性别以及手术中完全细胞减灭是改善发病率的有利预测因素。
根据我们的经验，CRS/HIPEC似乎对伴有同步肝转移和腹膜转移的PMP患者可行。
